Analyst ratings and price targets can significantly influence a stock's price. In this case, Canaccord Genuity has not only maintained a Buy rating on Throne Healthtech's stock, indicating a positive outlook, but also raised its price target from $6 to $7. This suggests that they believe the stock is undervalued at its current price, which could lead to increased buying pressure and a subsequent rise in the stock's price.